If our drug class is PI3K /mTOR why are they testing Paxalisib in the ALK/NTRK/ROS1 and not both? Shouldnt we be in 2/3 of the trial phase?
Copy of insert~ Advances in our ability to identify actionable mutations in patients with brain metastases have enabled the development of more advanced trial designs. The Alliance A071701 trial will build off these advances in patients with brain metastases, primarily from lung and breast primary tumors. In this trial, patients with progressive brain metastases who have tissue (brain or extracranial) available for sequencing will be assigned into 1 of 3 cohorts based on genetic alterations. Actionable alterations in the CDK pathway will be treated with abemaciclib as above. Mutations in the PI3K/AKT/mTOR pathways will be treated with the PI3K inhibitor entrectinib. Finally, patients with ALK/NTRK/ROS1 translocations will be treated with an inhibitor of this pathway, GDC-0084. The primary endpoint in this trial will be the CNS response rate.
KZA Price at posting:
77.5¢ Sentiment: Buy Disclosure: Held
